Search

Memorial Sloan Kettering Cancer Center (MSK) is proud to announce that Michel Sadelain, MD, PhD, renowned physician-scientist, Director of the Center for Cell Engineering, and Stephen and Barbara Friedman Chair, has been awarded the 2024 Breakthrough Prize in Life Sciences.

… Thursday, September 14, 2023 Memorial Sloan Kettering Cancer Center (MSK) is proud to announce that Michel Sadelain, MD, PhD, renowned physician-scientist, Director of the Center for Cell Engineering, and Stephen and Barbara Friedman Chair, has been awarded the 2024  Breakthrough Prize in Life Sciences

Bevacizumab (Avastin®) in combination with chemotherapy resulted in a clinical benefit for patients with recurrent ovarian cancer, according to a new study. Results from the phase III "OCEANS" trial were presented today by the lead author, Carol Aghajanian, MD, of Memorial Sloan Kettering Cancer Center, at the 2011 annual meeting of the American Society of Clinical Oncology.

… Saturday, June 4, 2011 Bevacizumab (Avastin®) in combination with chemotherapy resulted in a clinical benefit for patients with recurrent ovarian cancer , according to a new study. Results from the phase III “OCEANS” trial were presented today by the lead author, Carol Aghajanian, MD , of Memorial Sloan

Today Memorial Sloan Kettering (MSK) announced the appointment of a task force that will assess MSK policies and processes for reporting and managing outside activities and industry-supported clinical trials.

… Friday, September 21, 2018 Today Memorial Sloan Kettering (MSK) announced the appointment of a task force that will assess MSK policies and processes for reporting and managing outside activities and industry-supported clinical trials. The task force was announced in a statement from MSK President and

Learn how experimental vaccine might train the immune system to prevent pancreatic cancer from returning.

… Monday, June 10, 2024 Pancreatic cancer has long been a forbidding disease. While the five-year survival rate has inched upward in recent years, it remains quite low — about 12%. But surgeon-scientist Vinod Balachandran, MD , has focused on a glimmer of hope: A small percentage of people manage to beat

Discover what Memorial Sloan Kettering contributed to the science and medicine of x-rays.

… Tuesday, October 4, 2016 Summary Since 1902, Memorial Sloan Kettering has been a pioneer in the science and medicine of x-rays, developing many of the radiation techniques in use today. In a previous post , we recounted the history of radium therapy at Memorial Sloan Kettering. Radium, a naturally occurring

Investigators at Memorial Sloan Kettering Cancer Center, along with collaborating teams at the Cleveland Clinic and the University of Michigan, have completed the first large-scale, multi-institutional study of prostate cancer death after standard treatment to remove the prostate since PSA screening has become widely used as a method to screen for the disease.

… Monday, July 27, 2009 Investigators at Memorial Sloan Kettering Cancer Center (MSKCC), along with collaborating teams at the Cleveland Clinic and the University of Michigan, have completed the first large- scale, multi-institutional study of prostate cancer death after standard treatment to remove the

Learn about insights that could lead to a new class of drugs against cancers caused by RAS gene mutations.

… Wednesday, October 30, 2024 Each year, more than 3 million people are diagnosed with cancers driven by mutations in three RAS-family genes: KRAS, NRAS , and HRAS . RAS-family mutations are associated with numerous types of cancer. KRAS mutations are found in pancreatic cancer ,  colorectal cancer , 

Clues emerge about why promising new breast cancer drugs sometimes don’t work — and what might be done about it.

… Monday, December 10, 2018 Summary A new class of drugs called CDK4/6 inhibitors has been effective in women with breast cancer . However, some people don’t respond to the drugs, or they develop resistance over time. A study by MSK researchers has identified two genes linked to this resistance. The most

MSK performs the highest number of robot-assisted surgeries for colorectal cancer in the United States, enabling more patients to have a shorter hospital stay and a faster recovery.

… Thursday, March 14, 2024 When Robert Mendys was diagnosed with stage 3  rectal cancer  almost 10 years ago, he faced a profound dilemma. He wanted to make sure the cancer didn’t take him away from his wife and three young sons. But at only 46, he was very concerned about the long-term effects of surgical

MSK realiza la mayor cantidad de cirugías asistidas por robot para el cáncer colorrectal en los Estados Unidos, lo que permite que más pacientes tengan una estadía hospitalaria más corta y una recuperación más rápida.

… Thursday, March 14, 2024 Cuando Robert Mendys fue diagnosticado con cáncer de recto en estadio 3 hace casi 10 años, se enfrentó a un profundo dilema. Quería asegurarse de que el cáncer no lo alejara de su esposa y sus tres niños. Pero con solo 46 años, estaba muy preocupado por los efectos a largo plazo